Physician
Ages & Stages Pediatrics, PLLC
Ages & Stages Pediatrics, PLLC was paid $4.29M by Medicaid between Oct 2019 and Dec 2024, across 79 billing codes. Its largest line is 99214, doctor's office visit, returning patient (more involved) — 45% of everything it billed.
33Billing provider infoAGES & STAGES PEDIATRICS, PLLC
CHARLOTTE, NC 28210
CHARLOTTE, NC 28210
33aNPI1013489947assigned 12/17/2018
33bProvider typePediatrics Physician
28Total paid$4.29M
24GClaims167,286
24DCodes billed79
24AFirst – last monthOct 2019 – Dec 2024
Compared with peers
Next to other Pediatrics Physician providers in North Carolina
Rank by total paid#96 of 433
Median peer was paid$942K
This provider vs. median4.6×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2019 | 1,485 | $15K | |
| 2020 | 12,074 | $275K | |
| 2021 | 18,700 | $570K | |
| 2022 | 41,642 | $1.01M | |
| 2023 | 47,103 | $1.21M | |
| 2024incomplete | 46,282 | $1.21M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 45% | 22,411 | 13,945 | $1.93M |
| 99401 | 8.6% | 12,420 | 8,593 | $369K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 7.7% | 7,757 | 6,339 | $331K |
| 99392 | Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) | 4.6% | 2,225 | 1,731 | $197K |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 4.4% | 3,018 | 2,429 | $189K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | 3.4% | 5,846 | 3,896 | $145K |
| 99391 | Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) | 2.8% | 1,524 | 1,165 | $122K |
| 99393 | Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) | 2.4% | 1,189 | 942 | $104K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | 2.2% | 8,230 | 6,489 | $94K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | 2.2% | 8,128 | 6,578 | $92K |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | 2.1% | 5,918 | 4,236 | $89K |
| 90472 | Immunization administration, each additional vaccine (list separately) | 1.9% | 3,728 | 2,702 | $82K |
67 more codes
| 99199 | Unlisted special service, procedure or report | 1.9% | 20,848 | $80K |
| 99204 | Doctor's office visit, new patient (more involved) | 1.8% | 762 | $76K |
| 92587 | 1.4% | 3,844 | $60K | |
| 94664 | 1.1% | 5,627 | $48K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 1.0% | 2,503 | $44K |
| 96110 | Developmental screening, with scoring and documentation, per standardized instrument | 1.0% | 6,512 | $43K |
| 99394 | Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) | <1% | 333 | $32K |
| 88738 | <1% | 4,211 | $22K | |
| 99051 | <1% | 1,016 | $15K | |
| 99383 | <1% | 157 | $14K | |
| 83655 | <1% | 1,061 | $12K | |
| 80061 | Lipid panel | <1% | 1,040 | $11K |
| 98960 | <1% | 5,578 | $11K | |
| 99382 | <1% | 119 | $10K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 4,292 | $10K |
| 85018 | <1% | 4,422 | $8K | |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 48 | $7K |
| 96127 | <1% | 2,178 | $7K | |
| 69210 | <1% | 218 | $6K | |
| 87631 | <1% | 45 | $4K | |
| 90734 | <1% | 132 | $3K | |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 28 | $3K |
| 99173 | <1% | 3,518 | $3K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 48 | $2K |
| 88740 | <1% | 402 | $2K | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 62 | $2K |
| 0071A | <1% | 43 | $2K | |
| 87807 | <1% | 160 | $2K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 48 | $1K |
| 99381 | <1% | 18 | $1K | |
| 90710 | <1% | 322 | $1K | |
| 82270 | <1% | 288 | $1K | |
| 0072A | <1% | 13 | $780.00 | |
| 90460 | Immunization administration through 18 years of age via any route, first or only component | <1% | 386 | $568.54 |
| 99177 | <1% | 1,826 | $516.48 | |
| 90696 | <1% | 181 | $418.74 | |
| 90698 | <1% | 999 | $406.96 | |
| 90670 | <1% | 1,257 | $397.30 | |
| 92551 | <1% | 189 | $309.11 | |
| 92552 | <1% | 22 | $288.32 | |
| 90686 | <1% | 702 | $183.57 | |
| 90744 | <1% | 290 | $164.52 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 93 | $72.99 |
| 92558 | <1% | 279 | $62.48 | |
| 90654 | <1% | 74 | $60.99 | |
| 99188 | <1% | 57 | $38.85 | |
| 90633 | <1% | 538 | $32.66 | |
| 90700 | <1% | 77 | $27.87 | |
| 90461 | <1% | 76 | $23.76 | |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | <1% | 244 | $23.65 |
| 94760 | <1% | 224 | $21.18 | |
| 90658 | <1% | 45 | $18.87 | |
| 90680 | <1% | 725 | $14.92 | |
| J7510 | Prednisolone oral, per 5 mg | <1% | 16 | $0.72 |
| 90649 | 0% | 72 | $0.00 | |
| 99071 | 0% | 55 | $0.00 | |
| 90715 | 0% | 40 | $0.00 | |
| 90648 | 0% | 19 | $0.00 | |
| 90707 | 0% | 13 | $0.00 | |
| J7609 | Albuterol, inhalation solution, compounded product, administered through dme, unit dose, 1 mg | 0% | 5,302 | $0.00 |
| 90677 | 0% | 392 | $0.00 | |
| 90733 | 0% | 26 | $0.00 | |
| 99000 | 0% | 545 | $0.00 | |
| 91307 | 0% | 88 | $0.00 | |
| 87430 | 0% | 97 | $0.00 | |
| 90656 | 0% | 34 | $0.00 | |
| 90716 | 0% | 13 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialROSADO-JIMENEZ, ADRIANA (CEO)